Scope: Inadequate maternal folate intake is associated with increased childhood acute lymphoblastic leukemia (ALL) risk. Folate provides methyl groups for DNA methylation, which is dramatically disrupted in ALL. Whether or not maternal folate (and related B-vitamin) intake during pregnancy may affect ALL risk via influencing DNA methylation is investigated. Methods and Results: Genes in which methylation changes are reported both in response to folate status and in ALL are investigated. Folate-responsive genes (n = 526) are identified from mouse models of maternal folate depletion during pregnancy. Using published data, 2621 genes with persistently altered methylation in ALL are identified. Overall 25 overlapping genes are found, with the same directional methylation change in response to folate depletion and in ALL. Hypermethylation of a subset of genes (ASCL2, KCNA1, SH3GL3, SRD5A2) in ALL is confirmed by measuring 20 patient samples using pyrosequencing. In a nested cohort of cord blood samples (n = 148), SH3GL3 methylation is inversely related to maternal RBC folate concentrations (p = 0.008). Furthermore, ASCL2 methylation is inversely related to infant vitamin B12 levels. (p = 0.016). Conclusion: Findings demonstrate proof of concept for a plausible mechanism, i.e., variation in DNA methylation, by which low intake of folate, and related B-vitamins during pregnancy may influence ALL risk.
Introduction
Increasingly, evidence from epidemiological studies suggests that maternal folate intake prior to and during pregnancy may DOI: 10.1002/mnfr.201800411 influence the risk of the development of childhood acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] [5] [6] [7] The first study to report a protective association between maternal folate and ALL risk observed an odds ratio (OR) of 0.40 (confidence Intervals (CI) 0.21-0.73) for self-reported folate supplementation taken at any time, for any duration, during pregnancy. [7] Although this initial study was fairly small (83 cases and 166 controls), subsequent larger studies have also reported significant inverse associations between self-reported folate supplementation before or during pregnancy and ALL risk (OR = 0.4 (CI 0.3-0.6) [2] and 0.80 (0.71-0.89) [5] ). Further studies found associations between higher folate intake, assessed by retrospective food frequency questionnaires, at specific times during pregnancy and altered ALL risk. While Bailey et al. observed that higher dietary folate intake during the last 6 months of pregnancy was protective, [3] Singer et al. reported that higher maternal intake of one-carbon metabolism nutrients and supplements combined in the year before pregnancy reduced offspring ALL risk. [6] Similarly, Ajrouche et al. found that self-reported folate supplementation implemented 3 months preceding, but not during, pregnancy may reduce childhood leukemia risk (OR 0.7 (0.5-1.0)). [1] This www.advancedsciencenews.com
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Identify genes susceptible to changes in methylation in childhood ALL Data Source: Literature search [19, 20, [22] [23] [24] Identify genes susceptible to changes in methylation in response to altered folate
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Preclinical response Exposure
Preclinical response Clinical Disease Figure 1 . Schematic diagram of 'meet in the middle' study design, modified from Vineis and Perera. [40] Gene methylation responsive to maternal folate intake was identified via mouse models of folate depletion during pregnancy. Aberrant gene methylation in ALL was identified through compilation of data from the relevant literature. Gene sets were compared and methylation of four target genes was investigated in relation to maternal and infant folate status during pregnancy and at birth.
finding was supported by the largest meta-analysis to date, which observed that folate supplementation preconception reduces ALL risk (OR: 0.69, 95% CI: 0.50-0.95). [4] Furthermore, genetic studies investigating the influence of both parental and offspring variants of folate-metabolizing genes on childhood ALL risk corroborate the hypothesis that lower folate status may enhance disease risk. [2, [8] [9] [10] [11] [12] The observational evidence that in utero folate exposure may modulate risk of childhood ALL development is consistent but, to date, there is limited insight into the underlying mechanism through which folate status prior to, and during, pregnancy may be involved in disease development.
Childhood ALL arises from initial genetic abnormalities such as chromosomal rearrangement and hyperdiploidy. These abnormalities may occur in utero, [13] [14] [15] [16] [17] and remain latent until a 'secondary hit' leads to overt disease. Indeed, the ETV6-RUNX1 fusion, which occurs in 25% of B-cell precursor ALL cases, [18] was present in 1% of the population at birth; this is a 100-fold higher prevalence than for this disease subtype [16] suggesting that, while key in the disease pathway, the presence of this translocation alone is not sufficient to cause disease.
DNA methylation is an important mechanism of gene regulation and methylation of CpG rich regions may inhibit binding of the regulatory machinery and lead to gene silencing. [19] As with all cancers, altered DNA methylation patterns have been widely documented in ALL. [20] [21] [22] [23] [24] [25] [26] It is therefore plausible that gene dysregulation arising from aberrant DNA methylation may contribute to the etiology of childhood ALL, and thus be a potential 'second hit' mechanism in the causal disease pathway. Furthermore, while the DNA sequence is generally resistant to change in response to non-carcinogenic environmental factors, DNA methylation is more plastic and is altered by a variety of environmental and lifestyle exposures. [27] Since folate is a key source of methyl groups for synthesis of S-adenosyl methionine (SAM)-the universal methyl donor-it is an attractive candidate nutrient for the modulation of DNA methylation. Altered intakes of folate during pregnancy can have profound effects on DNA methylation patterns in the offspring, as has been reported in both animal models [28] [29] [30] [31] [32] [33] and human studies. [34, 35] It is therefore plausible that altered DNA methylation may be an underlying mechanism through which maternal folate intake prior to, and during, pregnancy may modulate risk of childhood ALL. Moreover, through their effects on the synthesis of SAM, related micronutrients driving one-carbon metabolism, i.e., vitamins B 2 , B 6 , and B 12 , may also modulate DNA methylation patterns and, hence, ALL risk. Indeed, higher maternal dietary B 12 intake has been associated with decreased offspring ALL risk, [3] and vitamin B 12 has also been reported to influence DNA methylation patterns. [36] [37] [38] [39] We therefore hypothesized that reduced intake of folate (and other B vitamins) during pregnancy may alter DNA methylation in genes that are also aberrantly methylated in childhood ALL. To investigate this hypothesis, we used a "meet in the middle" approach [40] to identify genes that have altered DNA methylation in response to maternal folate depletion and are also aberrantly methylated in childhood ALL (see Figure 1) . We utilized data from our mouse model of maternal folate depletion [29, 33] to determine genes which have altered methylation in response to maternal folate depletion. We then compared this list of genes with a compiled list of genes from the literature that have been reported to have altered DNA methylation in ALL. We confirmed aberrant DNA methylation in a panel of target genes in ALL patient samples, and investigated the association of maternal and infant folate and vitamin B 12 status on methylation of those loci in a population of healthy infants at birth. Altered DNA methylation in response to maternal folate depletion in fetal and adult mouse models has been previously reported. [29, 33] Briefly, female C57Bl/6 mice were randomized to low or normal folate diets (0.4 or 2 mg folic acid per kg diet) 4 weeks prior to mating. Mice were maintained on these diets throughout pregnancy, and throughout weaning (4 weeks) in the case of the adult offspring model. For the fetal model, dams were culled at 17.5 days' gestation, and fetuses removed. For the adult model of folate depletion during pregnancy, offspring were weaned on to diets containing normal levels of folate (i.e., 2 mg kg −1 ) and were maintained on this diet until 6 months of age. Low folate diets resulted in significantly lower folate status of dams compared to control fed dams (previously published data [41, 42] ). Fetal (n = 6/group) and adult (n = 12/group) livers were excised from male mice, and DNA extracted. Promoter methylation was measured by microarray analysis following methylated DNA immunoprecipatation. Resultant data were assessed for quality, normalized and processed as described previously. [29, 33] Using data from these studies, a list of 'folate-responsive' genes-i.e. those with altered DNA methylation in response to maternal folate intake in either fetal or adult offspring (n = 526 genes; See Supporting Information)-was compiled.
A list of genes reported to have altered DNA methylation in childhood ALL was determined using publically available data. A literature search was carried out in PubMed using the search terms "DNA methylation" and "childhood acute lymphoblastic leukaemia." The criteria for study selection were a) methylation had been assessed at the genome-wide level, b) methylation was compared in ALL cases versus control samples, c) methylation outcome data were available from the manuscript. Five studies were included for which genome-wide methylation had been assessed in childhood ALL cases compared with controls [20, 21, [23] [24] [25] (See Supporting Information for details) and a list of 2621 gene IDs was compiled including those genes for which altered methylation was reported in at least two of the selected studies (See Supporting Information).
Folate-responsive and ALL-associated gene lists were then compared using an online list comparison tool (http://jura.wi. mit.edu/bioc/tools/compare.php) with gene symbols as the common identifiers, and excluding case sensitivity.
Study Population (and Control Samples) and ALL Patient Samples
DNA methylation was measured at selected loci (ASCL2, KCNA1, SH3GL3, SRD5A2) in 20 DNA samples taken at diagnosis from either peripheral blood (n = 3) or bone marrow (n = 17) of ALL patients treated on the ALL97 trial. [18] Mean age of the patients was 1.15 years. Loci were selected based on having been reported in the literature to be aberrantly methylated in ALL and having had altered DNA methylation in response to modulated maternal folate intake in mice (as above). The purpose of these measurements was to confirm that the assay detected the expected (ALL-associated) changes in DNA methylation and hence was appropriate for use to measure DNA methylation at the same loci in samples for which data on human exposure to folate and other B vitamins in utero were available. These cases included KMT2A (MLL) rearrangements (n = 2), high hyperdiploidy (n = 7), and B-other subgroups (n = 11). Participating centers obtained approval from the local ethics committee and written informed consent from patients or parents. [18] The samples for which data on folate exposure were available was a nested cohort study population drawn from the North Cumbria Community Genetics Project, [43] which included 148 cord blood DNA samples (mean [± SD] gestation = 39.6 [1.3] weeks) in which gene-specific DNA methylation was measured. This prospective, unselected, population-based cohort was collected between 1996 and 2003 at a single maternity unit in West Cumbria, UK. Mothers were recruited at their first antenatal appointment (mean [SD] gestation = 10.8 [4.7] weeks) where they completed a health and lifestyle questionnaire and provided blood samples. Cord blood from the infant and delivery details were collected at birth. Maternal and infant (cord) red blood cell (RBC) folate and serum vitamin B 12 analyses were conducted on an aliquot of whole blood removed and stabilized prior to DNA extraction at the time of sampling-i.e., first trimester for maternal sample and at birth for cord blood samples. These samples were also used as the control population for comparison with DNA methylation patterns in ALL samples. Summary statistics are provided in the Supporting Information. Ethical approval to undertake this study was obtained from the Newcastle and North Tyneside Local Research Ethics Committee (07/Q0906/5). Written informed consent was obtained from all participating mothers recruited during pregnancy. Consent was obtained for use of biological samples (including DNA) from each mother-child dyad for epidemiological studies.
Bisulfite Pyrosequencing for Loci-Specific DNA Methylation Analysis
Bisulfite conversion of DNA was performed using the EZ DNA Methylation Gold kit (Zymo Research) following the manufacturer's protocol. Briefly, 500 ng of genomic DNA was incubated with a CT conversion reagent and incubated at the following temperatures; 98°C for 10 min, 64°C for 2.5 h, and held at 4°C. DNA was then transferred to a spin column, washed, desulphonated, and purified, finally eluting in a 10 μL volume.
Quantitative bisulfite Pyrosequencing was used to determine the percentage methylation at individual CpG sites within the promoter regions of the selected genes (number of CpGs: ASCL2, n = 7; KCNA1, n = 5; SH3GL3, n = 9; SRD5A2, n = 5). Briefly, 20 ng of bisulfite-treated DNA was added as a template in PCR reaction using 10 μL Hot Star Taq mastermix and 1 μL of each forward and reverse primer (Qiagen) in a total volume of 20 μL. All primer sequences and annealing temperatures for each assay are given in the Supporting Information. Amplification was carried out in a Veriti 96-Well fast thermocycler (Life Technologies) using the following protocol; 95 ᵒC for 15 min, then 50 cycles of 95 ᵒC for 15 s, assay-specific annealing temperature for 30 s, 72 ᵒC for www.advancedsciencenews.com www.mnf-journal.com 15 s, followed by 72 ᵒC for 5 min, and a final holding step at 4 ᵒC. Biotin-labeled PCR products were captured with streptavidin sepharose beads (GE Healthcare), and made single stranded using sodium hydroxide denaturation with the aid of a Pyrosequencing Vacuum Prep Tool (Qiagen). Sequencing primers were annealed to the single-stranded PCR product by heating to 80°C, followed by slow cooling. Pyrosequencing was then carried out on a Pyromark MD system. Cytosine methylation was quantified using proprietary PyroQ CpG 1.0.6 software. All PCR and Pyrosequencing reactions were carried out in duplicate.
For each assay, 0 and 100% methylated controls (Epitect, Qiagen) were routinely run alongside sample amplification as internal controls. Assays were validated to rule out any amplification bias of primers and to assess assay reproducibility using methods described previously. [44] All primer sets were found to be unbiased and assays were reproducible.
Statistical Analysis
To determine the distribution, one-sample Kolmogorov-Smirov tests were applied to CpG-specific and mean methylation data, with all data sets shown to be normally distributed. Pearson's correlation was used to assess correlation between percentage methylation at individual CpGs and mean percentage methylation across all CpGs for each gene. Significant correlations were observed for each individual CpG with mean methylation for all genes investigated (Supporting Information). To reduce false positive associations through multiple testing, initially mean methylation for each gene was examined in relation to the exposure variables maternal RBC folate, infant RBC folate, maternal vitamin B 12 , and infant vitamin B 12 using linear regression. Estimated power to detect a coefficient > 0.2 with a sample size of 148 is 68% at p = 0.05. For those genes where associations between exposure variables and mean methylation were found to be statistically significant (i.e., p-value < 0.05), each individual CpG in the given gene was analyzed in relation to the specific exposure variable of interest using linear regression. Comparisons of mean percentage methylation between "healthy" infants and ALL patients were analyzed by univariate ANOVA. Estimated power to detect a 10% methylation change assuming a conservative SD estimate of 9 in each group with an n = 20 is 94% at p = 0.05. All statistical analyses were performed using SPSS Version 19 software (IBM Statistical Package for the Social Sciences) and a p-value of <0.05 was considered statistically significant.
Results

Comparison of Folate and ALL-Associated Methylation Signatures
Of the 2621 genes reported to have altered DNA methylation in ALL in at least two studies, 793 did not have corresponding identifiers on the mouse array used to assess methylation changes in response to maternal folate depletion, and thus could not be directly compared. The remaining potentially comparable 1828 ALL-associated genes were compared with the 526 genes observed to have altered methylation associated with maternal folate depletion, with 66 genes found to overlap (Table 1) . Of these 66 genes, 34 were reported with a consistent direction of methylation change in ALL across at least two studies (i.e., 31 hypermethylated; three hypomethylated), and therefore considered for further analysis.
Twenty-five of the 34 genes (73.6%) that were reported to have a consistent direction of methylation change in ALL across studies displayed the same direction of methylation change in response to maternal folate depletion-i.e., hypermethylation. Of the 34 genes with consistent methylation change across studies, four were selected at random for DNA methylation quantification of the promoter region by pyrosequencing analysis (ASCL2, KCNA1, SH3GL3, and SRD5A2) . Methylation was assessed in ALL cases to confirm methylation at the region of the gene measured by these newly designed pyrosequencing assays was detectably higher in ALL disease samples compared with a healthy population (i.e., cord blood samples). While use of the cord blood samples as a comparator has limitations due to lack of age and sample type matching, it is appropriate in this instance to merely confirm the utility of the assays to capture ALL-associated hypermethylation previously reported elsewhere. As expected, mean methylation of all selected genes was statistically significantly higher in blood/bone marrow samples from ALL patients when compared with infant cord blood samples (Figure 2 ). We then subsequently tested for associations between DNA methylation and measures of folate and vitamin B 12 exposures.
Association between Maternal RBC Folate and Vitamin B 12 on Infant Gene Methylation at Birth
A statistically significant inverse relationship was observed between mean DNA methylation of the SH3GL3 gene and maternal RBC folate (p = 0.008; coefficient [95% CI] = 0.218 [-0.002 to 0.000]); Figure 3C ). This pattern of altered methylation was seen at multiple CpG sites across the region (Supporting Information). No associations were observed between mean methylation at the ASCL2, KCNA1, and SRD5A2 loci and maternal RBC folate status during pregnancy ( Figure 3A, B, and D) .
Furthermore, no associations were observed between the mean methylation of any of the loci investigated and maternal vitamin B 12 status (Figure 4). 
Association between Infant RBC Folate and Vitamin B 12 with Infant Gene Methylation at Birth
Mean methylation at the investigated loci was not significantly associated with infant RBC folate status at birth (Figure 5) .
A statistically significant inverse relationship was observed between mean methylation of the ASCL2 gene and infant vitamin B 12 concentration (p = 0.016; coefficient (95%CI) = 0.201 [-0.002 to 0.000]); Figure 6A ). This relationship was observed for multiple CpG sites across the region (Supporting Information). Mean methylation at the KCNA1, SH3GL3, and SRD5A2 loci were not significantly associated with infant vitamin B 12 status at birth (Figure 6B-D) . Denotes where reported direction of methylation change was consistent between studies, but both hyper-and hypomethylation were reported for that gene within one study.
Discussion
We hypothesized that, since folate is a key nutrient driving onecarbon metabolism toward the production of SAM for the methylation of biological molecules, aberrant DNA methylation may be an underlying mechanism for the observed inverse associations between maternal folate intake during pregnancy and childhood ALL risk. To investigate this hypothesis, we employed a "meet in the middle" approach [40] to identify overlap between folate and ALL-associated methylation signatures to test the plausibility that folate-associated altered methylation may be mechanistically involved in the causal pathway toward childhood ALL (Figure 1 ).
Of the genes reported to have a consistent direction of methylation change in ALL across studies (n = 34), 73.5% also displayed the same direction of methylation change in response to folate depletion. Thus, in individuals harboring ALL-initiating genetic abnormalities, maternal folate depletion may contribute to the causal disease pathway through altered DNA methylation of ALLassociated genes.
In this study, we utilized previously published data from our mouse model [29, 33] to identify genes with methylation change associated with maternal folate depletion. While human studies investigating the influence of maternal folate intake on offspring methylation have been conducted, there is a lack of reproducibility between these studies, with no concordant gene loci found between data sets (reviewed in ref. [45] ). While this is plausibly due to differences in sample type, study population (including genetic diversity), study design, platform used to assess methylation, and statistical analyses, confounding factors are likely to be major contributors to the observed differences between human studies. Since data derived from experimental studies in inbred models are not subject to the same level of reporting bias, genetic heterogeneity, and potential confounding factors as human studies due to more strict control of experimental parameters, this novel approach enabled us to include truly folate-responsive gene loci in our analysis. In this way, data from animal models may be useful in informing human studies where associations between environmental exposures and methylation patterns may be difficult to determine due to a) the difficulty in measuring or assessing certain exposures, b) the large numbers of participants required to reveal small changes in methylation in association with poorly defined exposure variables, and c) the large number of potential confounding factors in human studies.
It is pertinent to highlight, that the ALL-associated methylation signature was derived from studies measuring methylation in diseased cells, and therefore some of the aberrant methylation signatures is likely to be a consequence of disease rather than causal. Therefore, to distinguish those methylation marks that are causal for, from those that are consequences of, disease, measurements prior to diagnosis would be required. Given the rarity of childhood ALL and lack of available pre-diagnostic samples, currently very little is known about early initiating epigenetic events in the development of childhood ALL. The utilization of historical collections of neonatal blood spot samples or collective cases from multiple large cohort studies may facilitate investigation of pre-diagnostic methylation patterns, but are unlikely to have associated exposure data or may be underpowered to detect epigenetic changes in association with exposure. Therefore, novel methodologies, such as the current meet in the middle approach, are required to ascertain the plausibility of biological mechanisms by which environment may influence childhood ALL development. Further investigations using approaches such as one-and two-step Mendelian Randomization approaches [46] will be key in providing evidence of causality. To seek evidence for an effect of folate exposure in utero in humans on DNA methylation of genes found to be hypermethylated in ALL and therefore of potential relevance to disease causality, we assessed methylation of a subset of target genes (ASCL2, KCNA1, SH3GL3, and SRD5A2) in healthy newborns in relation to maternal and infant folate status, and in ALL patients. Given that folate and B 12 are key micronutrients driving one-carbon metabolism, and that maternal vitamin B 12 has been associated with offspring ALL risk, [3] we also investigated the association between maternal and infant B 12 status and methylation of these target genes. Lower maternal folate status was significantly associated with higher methylation of the SH3GL3 locus. Therefore, since low maternal folate is associated with increased ALL risk [1] [2] [3] [4] [5] [6] [7] and SH3GL3 hypermethylation is reported in ALL, [20, 21, 24] the observed association between low folate and SH3GL3 hypermethylation supports our hypothesis that low maternal folate intake during pregnancy may increase the risk of ALL via hypermethylation of the SH3GL3 locus. In particular, infants born to mothers with above normal (600 ng mL −1 ) RBC folate levels tended to have the lowest SH3GL3 methylation, which may indicate that higher than normal levels of folate are protective. This theory is supported by evidence that folate supplementation is protective against ALL. [1, 2, 4, 5, 7] We also report a significant inverse association between infant vitamin B 12 status and ASCL2 methylation. This finding is in keeping with the hypothesis that aberrant DNA methylation may be one potential biological mechanism facilitating the previously observed association between low vitamin B 12 status and ALL risk, i.e., low vitamin B 12 status may increase ALL risk through hypermethylation of ASCL2 and, possibly, other genes. [3] While the associations observed between SH3GL3 and ASCL2 methylation and maternal folate and infant B 12 status, respectively, are statistically significant, the range of methylation differences that we report are fairly small. While these relatively small changes in methylation in response to environmental factors are a common finding in epidemiological studies, [34, 47] the functional consequences of such small effects have often been questioned. It is important to bear in mind that, while DNA methylation is often reported as a percentage (i.e., reports the fraction of the DNA copies in a given sample that are methylated), methylation itself is a binary phenomenon, where for any given copy of DNA, specific CpGs are either methylated or unmethylated. It is therefore the methylation pattern of a specific cell that influences gene expression patterns of that individual cell. Should such epigenetic, and thus, gene expression changes occur in individual cells harboring pre-leukemic genetic aberrations, they may act as the "second hit" in the causal pathway, thus resulting in the transition to a leukemic cell.
While these findings support our hypothesis that altered DNA methylation may be a "second hit" that is causal for the development of ALL, it is pertinent to note we observed a significant association between folate status and methylation for only one of the four selected loci investigated. There are several potential explanations for this finding. It is plausible that the genes selected for investigation may not be folate-responsive in humans, or that methylation is altered at these loci only in response to more severe levels of depletion than were observed in this study (the majority [75%] of participants had folate levels within the normal range, i.e., 200-600 ng mL −1 ; with 7.4 and 17.6% being below and above these levels, respectively). Additionally, given the utilization of SAM across a range of biological pathways, the relationship between folate status, SAM, and DNA methylation is complex and therefore not always linear. Moreover, these relationships are highly tissue specific, therefore changes in gene-specific methylation observed in the murine liver in response to maternal folate intake may not be similar to folate responsive genes in human blood samples. Furthermore, while pyrosequencing is the gold standard measure of DNA methylation at specific CpG loci, this technique measures only a limited number of CpG's within a small genomic region (50-80 bp). It is, therefore, possible that methylation at other CpG sites not assayed here may be altered in response to low folate intake.
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Finally, the small population size (n = 148 mother-child dyads) may have limited our power to detect significant relationships between gene-specific methylation and B-vitamin exposure.
To our knowledge, this is the first study to address the potential for a plausible biological epigenetic mechanism through which low maternal folate status may adversely influence the causal pathway toward childhood ALL development. Furthermore, we provide proof of principle that the meet in the middle approach used to test our hypothesis (Figure 1 ) is effective in its triangulation of evidence for complementary sources, using data derived from animal studies to inform candidate markers of exposure in human studies. While further investigation of the role of DNA methylation in this disease pathway is warranted, this novel approach will allow further investigation of the role of folate (and other environmental factors) in ALL development. Improved understanding of the causes and underlying mechanisms that promote disease development, may lead to preventative (e.g., public health campaigns for improved nutrition during pregnancy) and predictive (e.g., biomarkers for high risk individuals such as those with Down syndrome) strategies, to reduce the burden of childhood ALL.
Supporting Information
Supporting Information is available from the Wiley Online Library or from the author.
